Company / Cost of Revenue
PUMA BIOTECHNOLOGY, INC. Cost of Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$62.7M
FY2025
5-year range
$36.8M / $63.7M
FY2021-FY2025
Trend
+13.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$63M in FY2025 with a 3-year CAGR of +16.8%.
Remained stable around $63M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +16.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +16.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 13.8% year-over-year.
- Peak cost of revenue was recorded in FY2023.
- Lowest cost of revenue in the period was in FY2018.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $62.7M | +13.8% |
| FY2024 | $55.1M | -13.5% |
| FY2023 | $63.7M | +61.8% |
| FY2022 | $39.4M | +7.0% |
| FY2021 | $36.8M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $5.6M | +0.0% |
| FY2017 | $5.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026